Committees

Future Cancer: NICE medicines appraisal (Enhertu)

Non-inquiry session

The committee will consider the impact of changes made by NICE to evaluate drugs used to treat patients with terminal illness like cancer in this session.

The Future Cancer inquiry received evidence from drugs’ companies that changes by NICE in 2022 on the cost-effectiveness of drugs for severe diseases do not sufficiently weight treatments used in advanced cancer. They say that as a result some cancer patients may miss out on last resort treatments.

MPs will also consider the breast cancer drug Enhertu which in draft guidance from NICE has not been recommended for treating secondary breast cancer in England.

The APPG on Breast Cancer will hold a roundtable event focusing on this issue later the same day.

Upcoming events

View all events

No upcoming events scheduled

Past events

Wednesday 8 May 2024
9:15am Private
9:30am Public
Future Cancer: NICE medicines appraisal (Enhertu) - Oral evidence 8 May 2024
9:30am
  • David Brocklehurst (Head of Oncology at AstraZeneca UK)
  • Haran Maheson (Vice President, Oncology at Daiichi Sankyo UK)
10:15am
  • Baroness Delyth Morgan (Chief Executive at Breast Cancer Now)
10:45am
  • Helen Knight (Director of Medicines Evaluation at National Institute for Health and Care Excellence (NICE))
  • Dr Sam Roberts (Chief Executive at National Institute for Health and Care Excellence (NICE))
Room 8, Palace of Westminster

Contact us

We receive a significant number of emails each day. All requests and invitations are considered but we do not respond directly to everyone. Please be aware, the committee does not look at individual cases or specific complaints.

  • Email: hsccom@parliament.uk
  • Address: Health and Social Care Committee, House of Commons, London, SW1A 0AA